EXPERIMENTAL APPROVAL OF THE EFFICACY OF THE COMBINED COMPOSITION RECTAL CREAM NEW TEST-SAMPLES IN THE CONDITIONS OF ACUTE COMPLICATED ANAL FISSURE IN RATS by Zaychenko, Ganna & Stakhorska, Marina
Original Research Article:
full paper
(2019), «EUREKA: Health Sciences»
Number 4
42
Pharmacology, Toxicology and Pharmaceutical Science
EXPERIMENTAL APPROVAL OF THE EFFICACY OF THE 
COMBINED COMPOSITION RECTAL CREAM NEW  
TEST-SAMPLES IN THE CONDITIONS OF ACUTE 
COMPLICATED ANAL FISSURE IN RATS
Ganna Zaychenko 
Department of Pharmacology
Bogomolets National Medical University
34 Peremogy ave., Kyiv, Ukraine, 03057
anna.zajjchenko@gmail.com
Marina Stakhorska 
Department of Clinical Pharmacology
Institute of Advanced Training of Pharmacy Specialists
National University of Pharmacy
53 Pushkinska str., Kharkiv, Ukraine, 61002
clinpharmacol_ipksph@nuph.edu.ua
Abstract
Anal fissure (AF) is one of the most common anorectal problems. The severity of the disease, the chronicity of the pathological 
process and frequent complications lead to a sharp deterioration in the quality of life of patients. An important place in the treatment 
of anal fissure is occupied by drugs that affect its key mechanism of pathogenesis, namely, reduce the muscle tone of the internal anal 
sphincter and have anti-inflammatory, analgesic, and reparative properties.
Aim: conducting of screening studies of the effectiveness of new test samples of rectal cream of the combined composition 
(RCCC) on the model of acute complicated anal fissure in rats and determining the optimal composition of the potential drug.
Materials and methods. The research was conducted on the basis of the Central Scientific Research Laboratory of the National 
Pharmaceutical University (CSRL NUPH) in the spring (April) season of 2015 on the female rats.
A study of test specimens of the rectal cream of the combined composition was performed on a modified model of acute anal 
fissure. The effectiveness of the treatment was evaluated in terms of (0 to 2) severity of edema, hyperaemia, local bleeding, purulent 
necrotic processes, scapular formation, anatomical defect, and a general indicator of the severity of the pathological process (by the 
sum of the points for all the criteria that were analyzed). The level of proinflammatory PGE2 in serum was determined by the immune 
enzyme method.
Results. The RCCC sample No. 4 showed the most expressive therapeutic effect among the four samples under study, and 
had credible benefits to the inhibitory effect on purulent-necrotic processes, as expressed by the differences in the overall rate of the 
pathological process (6 days: 5.83±0.47 points against 7.00±0.37; 7.83±0.31 under the influence of RCCC No. 2, No. 3, respectively, and 
for 11 days 5.00±1.03 versus 6.83±1.28 points (p=0.08 ) under the influence of RCCC No. 1). The ability of RCCCs No. 1 and No. 4 to 
reduce the level of pro-inflammatory PGE2 in blood serum of rats compared with CP in 1.8 and 2.0 times, respectively, contributed to 
accelerating epithelization and scar formation. The advantages of RCCC No. 4 on the comparison of the ointment “Proctozan” with the 
reduction of the period of epithelization of the defect of the mucous membrane of the anal canal for 3 days (for 7 days – RCCC No. 4, 
for 10 days – ointment “Proctozan”).
Conclusions. The rectal cream of the combined composition No. 4 showed the greatest efficacy, had advantages over the com-
parison ointment “Proctozan”, and is promising for the creation on its basis a new drug for the treatment of anal fissures.
Keywords: rectal cream of combined composition, acute experimental anal fissure, prostaglandin E2.
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1. Introduction 
Anal fissure (AF) is one of the most common anorectal problems [1, 2]. According to vari-
ous authors, the proportion of patients with AF in the structure of colorectal disease is from 8.5 to 
16.0 %, women suffer from 1.5 to 2.0 times more often than men [3]. The disease dramatically 
worsens the quality of life of patients, makes them conflict and annoying, negatively affects the 
general and psychological state [4, 5].
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The pathological process with acute and chronic AF is characterized by a set of typical 
symptoms (inflammation, pain, microcirculatory vascular disorders and dysfunction of the sphinc-
ter apparatus) that develop simultaneously. One of the most important pathogenetic mechanisms 
that lead to tissue ischemia in the AF localization zone is the persistent spasm of the internal anal 
sphincter [1, 4].
The basis of the modern concept of pharmacotherapy AF [4, 6] is the use of drugs, such as 
calcium antagonists, nitrates, botulotoxin, whose action is aimed at eliminating the hypertonicity 
of the internal anal sphincter (IAS), which is the main factor in the chronicization of the patholog-
ical process [5, 7].
Most of the drugs presented today in the pharmaceutical market of Ukraine [8, 9] for the 
treatment of this pathology contain the following composition of active substances: local anaes-
thetics, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), heparin, phenylephrine, 
ihtiol, vegetable components, mainly in the combined form, less commonly monopreparations. 
However, their application provides only symptomatic effects aimed at eliminating the inflam-
matory and pain syndrome, the sense of itching and burning in the anorectal area, stopping the 
bleeding and stimulating reparative processes. In fact, none of these drugs has a pathogenic effect, 
which helps to eliminate, first of all, spasm of muscle tissue IAS.
Thus, the analysis of the modern range of medicines in the Ukrainian pharmaceutical mar-
ket shows a complete lack of drugs, the composition and effect of which would correspond to new 
approaches to medical treatment of AF [4, 6]. Taking into account the above, the development and 
introduction into clinical practice of drugs of Ukrainian origin, which would be able to influence 
the main pathogenesis pathways and main clinical manifestations of AF, is one of the most urgent 
tasks of pharmacology and coloproctology.
2. Aim at research 
Conducting screening studies on the efficacy of new test samples of rectal cream of com-
pound composition (RCCC) on acute complicated AF models in rats and determining the optimal 
composition of a potential drug.
3. Materials and Methods 
In the screening studies conducted in the spring (April) season in 2015, four RCCC test 
samples were used that were developed at “Institute for Single Crystals” of the National Acad-
emy of Sciences of Ukraine under the direction of doctor of pharmaceutical sciences, professor 
Lyapunov M. O.
RCCC test samples are white, homogeneous, odourless, opaque, containing active ingredi-
ents: diltiazem hydrochloride, lidocaine hydrochloride and methyluracil, but differ in their quanti-
tative content. Data are given in Table 1.
Table 1
Composition of new test specimens of rectal cream of combined composition (RCCC) proposed for the 
treatment of anal fissure
Active ingredients Test sample No. 1 Test sample No. 2 Test sample No. 3 Test sample No. 4
Diltiazem hydrochloride, mg/ml 40 40 40 20
Lidocaine hydrochloride, mg/ml 30 30 30 30
Methyluracil, mg/ml 50 0 100 50
The comparator preparation was rectal ointment “Proctozan” produced by Stada Arzneimit-
tel AG, Germany (composition: 50 mg bufexamac, 50 mg bismuth subgallate, 50 mg titanium diox-
ide, 5 mg lidocaine hydrochloride) [8].
The study of the effectiveness of these RCCC test samples was performed on 36 non-linear 
white rats in females weighing 200–240 g in the model of acute complicated AF [10] under conditions 
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of its modification [11]. Animals under novocaine anesthesia (0.1 mg of 0.5 % solution of novocaine 
hydrochloride) were injected into the submucosal membrane of the posterior wall of the anal canal in 
the area of skin transition in anoderm 0.1 ml of 2 % formalin solution. AF was modelled by a scalpel 
dissection of the mucous membrane on the back of the anal canal (at 6 o’clock under the conditional 
dial at the position of the rat on the back), forming a defect – a linear wound of 5×2×1 mm.
All animals were divided into 6 experimental groups of 6 rats each.
Group 1 – group of animals intact control; 2 – animals with non-treated AF (control pathol-
ogy, CP); 3, 4, 5, 6 groups – animals with AF that were treated by RCCC No. 1, No. 2, No. 3, No. 4, 
respectively; group 7 – animals, who were treated with comparison ointment “Proctozan”.
Treatment of rats began after 24 hours after AF recreation. The test samples and the compar-
ator preparation were injected into the anal canal with an insulin syringe with a blunt needle in the 
amount of 0.3 ml once daily throughout the experiment (12 days). At day 12, rats were withdrawn 
from the experiment by decapitation under a light ethereal anaesthetic.
The effect of the studied RCCC samples and “Proctozan” ointment on the course of the 
pathology was evaluated daily by the following parameters: severity of edema, hyperaemia, lo-
cal bleeding, purulent necrotic processes, formation of scab and anatomical defect. Evaluation of 
pathological changes for each of the listed indicators was carried out on a scale: 0 points – absent 
or weak changes; 1 point – moderately pronounced changes; 2 points – pronounced changes. The 
effectiveness of treatment was characterized by each individual indicator under study and by the 
general indicator of the severity of the pathological process – the sum of the scores for all the indi-
cators that were analyzed.
At the end of the experiment, in the blood serum of rats, the level of the major prostaglandin 
E2 (PGE2) [12] was determined by the enzyme-linked immunosorbent assay method of the General 
Prostaglandin E2 ELISA Kit (EIAab, Cat. N: E 0538 Ge, China) according to the instructions. The 
incubation was carried out on a thermostat shaker ImmunoChem-2200 (HTI, USA), and the optical 
density of the samples was determined using a microplate reader of ImmunoChem-2100 (HTI, 
USA). For comparison with the magnitude of the physiological norm, PGE2 level was determined 
in intact animals (intact control, 6 rats).
The research was conducted in the Central Research Laboratory of the National Pharma-
ceutical University (CSRL NUPH), certified by the SEC of the Ministry of Health of Ukraine 
(certificate No. 058/15 dated December 8, 2015, valid until 07.12.2019). During the experiment, the 
animals were kept in the CSRL NUPH vivarium at a temperature of 20–22 °C and 50 % humidity 
in a well ventilated room, under the conditions of natural day and night light (April 2015) with free 
access to food and water.
All manipulations with animals were carried out in accordance with the requirements of 
GLP, the recommendations of the SEC of the Ministry of Health of Ukraine, the National “Gen-
eral ethical principles of animal experiments (Ukraine, 2001), the Law of Ukraine No. 3447-IV of 
February 21, 2006, as amended “On the protection of animals from cruel treatment” by the deci-
sion of the first national congress on bioethics (Kyiv, 2007) [13] and “European Union Directive 
2010/63 / EU on the protection of animals used for scientific purposes” [146].
The statistical processing of the obtained results was carried out using parametric (Student’s 
criterion) and non-parametric (Kruskal-Wallis criterion) methods of statistics. The level of signifi-
cance p<0.05 [15] was adopted.
4. Results of researches 
After simulating acute AF, the development of pathological process in animals from the CP 
group was characterized by a certain dynamics of clinical symptoms: edema, hyperaemia, local 
bleeding, and purulent necrotic processes.
Inflammation, evaluated for the severity of such clinical symptoms as swelling and hyper-
aemia, were maximum (2.00±0.00 points) from 1 to 10 days with a slight decrease over the last two 
days of the trial. Local bleeding occurred only on the first day and was present in a small number 
of animals (in two of six) at the end of the experiment (11 days). Manifestations of purulent ne-
crotic process in untreated animals began with 4 days (0.67±0.21 points) and reached a maximum 
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of 9 and 10 days (1.67±0.33 points), indicating the probable accession of the infection and chronic 
pathological process (Fig. 1).
Fig. 1. Significance of purulent necrotic process under the influence of RCCC test specimens on 
the model of acute complicated anal fissure in rats (points): * – significant differences in control 
pathology (nonparametric criterion of Kruskal-Wallis), p<0.05; ** – the differences are relative 
to the drug comparison ointment “Proctozan” (nonparametric criterion Kruskal-Wallis), p<0.05; 
# – the differences are relative to RCCC № 4 (nonparametric criterion of Kruskal-Wallis), p<0.05; 
T – trend 0.050<p<0.1
The expressiveness of the scab formation was variable: it marked its appearance from 4 to 
6 days, the absence in the period of intensification of the development of purulent necrotic process-
es from 6 to 10 days and during the last two days, due to a decrease in necrosis of the mucous mem-
brane of the anal canal in the affected area. The severity of the anatomical defect in animals from 
the CP group was maximal (2.00±0.00 points) from day 1 to day 9 of the experiment and slightly 
decreased (to 1.83±0.17 points) during the last three days of the experiment.
The general indicator of the severity of the pathological process was 8.00±0.00 points for the 
first day, decreased to a minimum value of 6.33±0.26 points for 2 and 3 days, followed by a maximum 
increase to 7.67±0.33 points at 9 day At day 12 of the experiment, the severity of the pathological process 
in untreated animals was quite significant at the level of 7.00±0.68 points out of 12.00 possible (Fig. 2).
Fig. 2. The general indicator of the severity of the pathological process (in total, according to the 
studied parameters) under the influence of RCCC test samples on the model of acute complicated 
anal fissure in rats (points): * – significant differences in control pathology (nonparametric 
criterion of Kruskal-Wallis), p<0.05; ** – the differences between the “Proctozan” ointment 
(nonparametric Kruskal-Wallis criterion) p<0.05; ¥ – the differences are relative to RCCC No. 1 
(nonparametric criterion of Kruskal-Wallis), p<0.05; ¶ – the differences are relative to RCCC No. 2 
(nonparametric criterion of Kruskal-Wallis), p <0.05; & – the differences are relative to RCCC 
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Comparative drug, “Proctozan” ointment, on the background of complicated acute AF 
showed a significant anti-swelling (1.17±0.17 points versus 2.00±0.00 points of CP) and antihyper-
emic effects, the maximum of which occurred at 3 days. Since 4 days, the therapeutic effectiveness 
of “Proctozan” ointment has decreased and during the period from 5 to 12 days of the experiment 
there was no difference in the overall indicator of the severity of the pathological process in relation 
to the CP group (Fig. 2).
Two RCCC test samples, number 1 and number 4, starting from 5 days, demonstrated the 
ability to reduce the expressiveness of purulent necrotic processes and accelerated reparation. At 
day 7 of the experiment in single rats under the influence of RCCC No. 4, the beginning of epithe-
lization was noted, and the first case of epithelization in animals treated with “Proctozan” ointment 
was recorded for only 10 days.
At 10-12 days, the severity of purulent-necrotic processes in some rats that received test 
specimens No. 1, No. 2, No. 3, and the comparison drug, increased somewhat.
RCCC No. 4 showed the most expressive therapeutic effect and had significant benefits 
to the inhibitory effect on purulent-necrotic processes (for 7 days, the test was 0.17 points versus 
1.00±0.26, 1.00±0.37 and 1.33±0.33 points, respectively, under the action RCCC No. 1, No. 2, No. 3); 
anatomical defect (for 4 days 1.50±0.22 points against 2.00±0.00 points under the influence of 
RCCC No. 1, No. 2, No. 3 (p=0.05)). The reliable differences of the general indicator of the expres-
siveness of the pathological process for 6 days are established: 5.83±0.47 points versus 7.00±0.37; 
7.83±0.31 under the influence of RCCC No. 2 and No. 3, respectively, and for 11 days (5.00±1.03 vs. 
6.83±1.28 points (p=0.08) under the influence of RCCC No. 1).
Also, the effect of RCCC test samples on the level of PGE2 in blood serum of rats was eval-
uated. Data are given in Table 2.
Table 2
The content of PGE2 in blood serum of rats with acute anal fissures at 12 days of the experiment under the 
influence of RCCC test specimens (n=6)
Experimental group The content of PGE2 in blood serum, pcg/ml
Intact control 230.3±57.6
CP 485.5±82.6*
RCCC No. 1 275.8±13.4**
RCCC No. 2 354.8±23.3***
RCCC No. 3 361.5±54.8***
RCCC No. 4 245.0±60.1**
«Proctozan» ointment 237.9±8.5**
Note: * – the differences are reliable for intact control, p<0.05; ** – the differences are reliable for the CP, p<0.05; *** – the differ-
ences are reliable with respect to the drug comparison ointment “Proctozan”, p<0.05
The level of PGE2 in the blood serum of rats from the CP group at 12 days of the experiment 
was 2.1 times higher (p<0.05) higher than intact control. The content of PGE2 in blood serum of 
animals treated with RCCC No. 2 and No. 3 was also high (354.8±23.3 and 361.5±54.8), almost at 
the level of animals in the CP group. At the same time, there was a significant decrease in PGE2 
to the level of intact control in rats treated with RCCC No. 1 and No. 4 (respectively, 75.8±13.4 and 
245.0±60.1). “Proctozan” ointment contributed to reduce the level of PGE2 to intact control.
5. Discussion
It was established that the reproductive model of the acute complicated anal fissure in rats 
was characterized by the progressive dynamics of edema, hyperaemia, significant pronounced pu-
rulent necrotic processes, the formation of scab, and the formation of anatomical defect, which 
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remained until the end of the experiment. Such dynamics of pathological changes in the control 
group of animals is probably related to the action of formalin, which causes the destruction of pro-
teins and other cellular components and leads to necrosis of tissues [11]. The level of PGE2 in blood 
serum from the CP group of rats, despite the individual cases of complete healing of the anatomical 
defect at day 12 of the experiment, remained significantly elevated by 2.1 times (p<0.05) compared 
with intact control.
Two RCCC test samples, No. 1 and No. 4, starting from 5 days, demonstrated the ability to 
reduce the expressiveness of purulent necrotic processes and accelerated reparation. At day 7 of 
the experiment, under the influence of the RCCC sample number 4, epithelization was noted in one 
rat, and the first case of epithelization in animals treated with “Proctozan” ointment was recorded 
for only 10 days.
The expressiveness of purulent necrotic processes in some rats who received test specimens 
No. 1, No. 2, No. 3 and the comparison preparation, increased somewhat for 10-12 days, indicating 
the tendency to chronization of the process. 
RCCC No. 4 showed the most expressive therapeutic effect and had credible advantages 
over RCCC No. 1, No. 2 and No. 3 for the inhibitory effect on purulent-necrotic processes on day 
7 of the trial; on the severity of the anatomical defect (4 days), which was expressed by the differ-
ences in the overall indicator of the severity of the pathological process by 6 days, compared with 
RCCC No. 2, No. 3 and 11 days compared with RCCC No. 1.
The comparison drug “Proctozan”, which was used in the experiment, made the most 
expressive anti-swelling and antihyperemic effects, with a maximum effect of 3 days. It had a 
significant anti-inflammatory effect and superiority to all the test samples tested, which in con-
trast to it practically did not affect the severity of inflammation. This fact, obviously, is related to 
the presence of “Proctozan” ointment, a buffer that acts according to the mechanism of action, is 
a typical NSAID [16] and distinguishes it from the test samples tested, which do not contain any 
components that exhibit would have a clear anti-inflammatory effect. Since 4 days, the therapeu-
tic efficacy of the “Proctozan” ointment has decreased and during the period from 5 to 12 days of 
the experiment, there was no difference in the overall indicator of the severity of the pathological 
process in relation to the CP group. The explanation for such an action by the “Proctozan” oint-
ment is more likely to be that all anti-inflammatory agents, reducing the severity of the changes 
that make up the nature of acute inflammation, eliminate its completion and inhibit the reparative 
processes [17, 18], as well as those available in its composition does not reduce the tone of the 
internal anal sphincter muscles.
Given the important role of prostaglandins, in particular PGE2, in initiating and developing 
inflammation (redness, swelling, pain) accompanying the wound [12], it was advisable to evaluate 
the effect of the tested RCCC samples on their blood serum level in rats.
The level of PGE2 in the blood serum of rats from the CP group, despite the individual 
cases of complete healing of the anatomical defect at day 12 of the experiment, remained signifi-
cantly elevated, which is probably due to the spraying of pronounced acute inflammatory changes 
to reparative processes that have already been activated. Such a character of the development of 
pathology is accompanied by excessive accumulation of connective tissue elements, a violation of 
epithelization and the formation of scar [19, 20]. Low levels of PGE2 in blood serum of animals 
treated with “Proctozan” ointment were due to the presence of an anti-inflammatory agent, bufexa-
mac, which could lower the level of PGE2 [8]. However, it has been established that the “Proctozan” 
ointment was somewhat less effective compared to the RCCC sample No. 4 as a general indicator 
of the pathological process.
The content of PGE2 in blood serum of animals treated with RCCC No. 2 and No. 3 was 
practically at the level of animals from the CP group, indicating that the pathological process was 
chronic. At the same time, there was a significant decrease in PGE2 levels to the level of intact con-
trol in rats treated with RCCC No. 1 and No. 4, indicating attenuation of inflammation after 10 days 
of the experiment against the backdrop of positive dynamics of reparative processes.
Consequently, according to the results of screening studies, a perspective test for RCCC 
No. 4 was found to be the most effective in the acute complicated AF model. 
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6. Conclusions
1. Model pathology of acute complicated AF in rats was characterized by the progressive 
dynamics of development of clinical symptoms (edema, hyperaemia), expressiveness of purulent 
necrotic processes, formation of scab, and formation of anatomical defect against a background of 
elevated level of pro-inflammatory PGE2 in 2.1 times (p <0.05 ) for 12 days, indicating the chroni-
cization of the pathological process.
2. RCCC test sample No. 4 showed the most expressive therapeutic effect among the four 
test samples and had significant advantages over the inhibitory effect on purulent necrotic pro-
cesses, as evidenced by the differences in the overall rate of the pathological process (6 days: 
5.83±0.47 points against 7.00±0.37, 7.83±0.31 under the influence of RCCC No. 2 and No. 3, 
respectively, and for 11 days 5.00±1.03 against 6.83±1.28 points (p=0.08) under the influence 
of RCCC No. 1). The ability of RCCCs No. 1 and No. 4 to reduce the level of pro-inflammatory 
PGE2 in blood serum of rats compared with CP in 1.8 and 2.0 times, respectively, contributed to 
accelerating epithelization and scar formation.
3. The advantages of RCCC No. 4 on the comparison ointment “Proctozan” with the reduc-
tion of the period of epithelization of the mucous membrane defect of the anal canal for 3 days were 
established (in 7 days RCCC No. 4, in 10 days “Proctozan” ointment was better).
4. The results of the RCCC No. 4 largest therapeutic effects substantiate the optimality of 
its composition and the expediency of further in-depth study to create a new domestic drug for the 
treatment of coloproctological diseases, in particular AF.
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Abstract
The aim of the study is to develop a method for forecasting the indicators for drug reimbursement to patients with cardiovascular 
diseases (CVD) in Ukraine within the framework of the government program “Available medicines”. 
Materials and methods: materials of the State Statistics Service of Ukraine and medical records of patients with CVD, who 
were prescribed with medicines according to the government program, were used in the study. 
Results: according to the method proposed for forecasting the volume of drug reimbursement to patients with CVD under the 
government program it has been found that Enalapril has the highest indicator – 10916.4 USD thousand in 2019 and 10736.8 USD thou-
sand in 2020. Clopidogrel takes the second position – 12108.13 USD thousand and 11908.24 USD thousand, while Amlodipine occupies 
the third position – 9105.60 USD thousand and 8955.28 USD thousand. 
Among the medicines not included in the government program, but prescribed rather frequently the largest forecasting amount 
required for reimbursement (in case of inclusion in the program) is 18910.55 USD thousand in 2019 and 18598.36 USD thousand in 2020 
for Magnicor, and the least amount is 444.55 USD thousand and 437.22 USD thousand for Acetylsalicylic acid, respectively. 
Conclusions. The government program to provide patients with effective and affordable medicines has a significant impact 
on reforming the healthcare system of Ukraine. The study conducted can be used to expand the government program in the process of 
formation and distribution of budget funds.
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